Literature DB >> 27402577

Haematological cancer: Obinutuzumab effective against treatment-refractory NHL.

Peter Sidaway.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27402577     DOI： 10.1038/nrclinonc.2016.112

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

Authors:  Laurie H Sehn; Neil Chua; Jiri Mayer; Gregg Dueck; Marek Trněný; Kamal Bouabdallah; Nathan Fowler; Vincent Delwail; Oliver Press; Gilles Salles; John Gribben; Anne Lennard; Pieternella J Lugtenburg; Natalie Dimier; Elisabeth Wassner-Fritsch; Günter Fingerle-Rowson; Bruce D Cheson
Journal:  Lancet Oncol       Date:  2016-06-23       Impact factor: 41.316
  1 in total
  1 in total

1.  Global, regional and national burden of non-Hodgkin lymphoma from 1990 to 2017: estimates from global burden of disease study in 2017.

Authors:  Haifeng Sun; Li Xue; Yahuan Guo; Jianqiang Du; Kejun Nan; Ming Li
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.